While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

A functional malaria vaccine was developed in the 1990s but took decades to reach patients. The delay was not scientific but economic; since it primarily affects poor nations, pharmaceutical companies had no profit motive to fund the necessary large-scale trials and distribution.

A key tension is emerging in orphan drug development. While the FDA's approval standards appear to be rising and becoming more erratic, Congress has simultaneously created a powerful economic incentive by exempting orphan-only drugs from Medicare price negotiation, creating a complex strategic landscape.

The Orphan Drug Act successfully incentivized R&D for rare diseases. A similar policy framework is needed for common, age-related diseases. Despite their massive potential markets, these indications suffer from extremely high failure rates and costs. A new incentive structure could de-risk development and align commercial goals with the enormous societal need for longevity.

Renowned gene therapy pioneer Jim Wilson was forced to spin out ultra-rare disease programs into a new company after his initial venture failed to attract VC funding. This demonstrates that even elite scientific leadership cannot overcome investor disinterest in this segment without powerful, predictable government incentives like transferable priority review vouchers.

The debate over Thymosin alpha-1 highlights a key market failure. Because it's an existing molecule that is difficult to patent, major pharmaceutical companies lack the financial incentive to fund expensive US FDA trials. This creates a vacuum where a potentially effective drug is only accessible through unregulated channels.

The standard patent system, which rewards innovation through high prices, is inefficient for creating products for the poor like vaccines. Advanced Market Commitments (AMCs) solve this by creating a pull mechanism: a legally binding promise to buy a large quantity at a set price, guaranteeing a market and aligning incentives for innovation.

Both in the US (with Medicare/Medicaid) and China, the areas of medicine that see the most government spending on drugs also attract the most R&D investment. China strategically uses this mechanism to direct innovation towards its public health priorities.

For diseases affecting only the poorest populations, scientific success isn't enough. The key financial instrument is an "advanced purchase" guarantee from a government or large organization. This de-risks production for manufacturers, providing a viable business model where traditional profit motives fail.